The development of verubecestat and its trials, at a combined cost of over billion dollars, constituted the “dream experiment”, referred to above, and validated the notion of AβPP-independent generation of C99 in Alzheimer’s disease. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.